NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will participate in two investor conferences in September:
A webcast replay will be available following the conferences and may be accessed on the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.
Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)…
Burlington, Ontario--(Newsfile Corp. - June 25, 2024) - Rapid Dose Therapeutics Corp. ("RDT" or the…
DUBAI, UAE, June 25, 2024 /PRNewswire/ -- Hisense, a leading global home appliance and consumer…
Move highlights division's growth; brings on noted industry experts Matt High and Elijah MarentetteTARRYTOWN, NY…
UPPSALA, SE / ACCESSWIRE / June 25, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime AB (publ.) announced…
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (FSE:…